OGC
IOVA icon

One68 Global Capital’s Iovance Biotherapeutics IOVA Stock Holding History

One68 Global Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$55K – 54
2025
Q4 		$55K Buy
+20,000
New +$46.3K 0.65% 33
2025
Q2 		– Sell
-10,000
Closed -$33.3K – 38
2025
Q1 		$33.3K Hold
10,000
– – 0.02% 90
2024
Q4 		$74K Buy
+10,000
New +$92.7K 0.04% 89

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

One68 Global Capital's IOVA Position: Q1 2026 in Review

One68 Global Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 20,000 shares — an estimated $55K sold.

One68 Global Capital first reported a position in IOVA in Q4 2024 and held it in 3 quarters. The position peaked at $74K in Q4 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • One68 Global Capital reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • One68 Global Capital sold 20,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $55K.
  • One68 Global Capital first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 3 quarters.
  • One68 Global Capital's Iovance Biotherapeutics position peaked at $74K in Q4 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on One68 Global Capital's 13F filing for Q1 2026, filed 15 May 2026.